SMAD4 and KRAS status shape malignant-stromal crosstalk in pancreatic cancer
E. G. Lloyd, M. Jihad, J. S. Manansala, W. Li, P. S. Cheng, S. P. Teles, G. Mucciolo, J. A. Henriquez, S. Ashworth, W. Luo, S. Harish, P. M. Johnson, L. Veghini, M. Zaccaria, R. Brais, , G. Biffi
This study shows that SMAD4 and KRAS mutations influence stromal composition and therapeutic response in pancreatic cancer models.
bioRxiv · Apr 28, 2024Cancer Biology